aspirin in a regular dose. To determine whether 50 mg/day is as effective as 100 mg/day for the prophylaxis of microvascular circulation disturbances in essential thrombocythemia, a randomized trial comparing low-dose aspirin 50 mg versus 100 mg at platelet counts between 400 and 1,000 up to 1,500 x 10 9 /L is recommended. To address the question whether reduction of the platelet count to normal (<350 x 10 9 /L) is as effective as low-dose aspirin for the long-term relief of microvascular circulation disturbances, a randomized study comparing low-dose aspirin with the correction of platelet count to normal by anagrelide is recommended. High-risk essential thrombocythemia patients have a clear indication for platelet reductive therapy, including: (a) platelets >1,500 x 10 9 /L, history of major thrombosis (myocardial infarction, stroke, peripheral occlusive vascular disease), or presence of vascular disease (e.g., arteriosclerosis); (b) history or presence of spontaneous or major bleedings, bleedings elicited by low-dose aspirin for the secondary prevention of vascular complications in essential thrombocythemia at platelet counts <1500 x 10 9 /L, and side effects of long-term aspirin treatment such as gastritis; and &copy; progression from lowto high-risk essential thrombocythemia patients during follow-up or progressive myeloproliferative disease such as significant splenomegaly, myelofibrosis, leukocytosis, etc. To address the question of optimal treatment of high-risk essential thrombocythemia patients, randomization for anagrelide versus interferon at < 65 years of age and anagrelide versus hydroxyurea at an age > 65 years is recommended.
The broad spectrum of acroparesthesias, erythromelalgia and acrocyanotic ischemia; or gangrene of one or more toes together with the episodic symptoms of vertigo, migraine, attacks of amnesia, dysphasia, dysbasia, transient ischemic attacks, hemiparesis, and seizures are linked to essential thrombocythemia (ET) in which platelet-mediated inflammatory and thrombotic processes in the endarterial microvasculature reflect the existence of a platelet-dependent arterial thrombophilia in thrombocythemia vera (1) (2) (3) (4) (5) (6) (7) (8) . The increased platelet number and an unknown qualitative platelet defect in thrombocythemia vera are postulated to lead to an increased risk of plateletmediated thrombotic complications involving the peripheral, coronary, and cerebral endarterial circulation (4) (5) (6) (7) (8) .
In contrast to the inefficacy of coumarin (1, 4) , control of platelet function with low doses of aspirin and cytostatic reduction of platelet counts to normal in thrombocythemia prevent the recurrence of microvascular circulation disturbances and, probably, most major arterial thrombotic events, including minor strokes, angina, and myocardial infraction (1-9).
LOW-AND HIGH-RISK ET PATIENTS
It has been demonstrated that age was not a risk factor for microvascular circulation disturbances and arterial thrombosis in 69 ET patients described by van Genderen et al. (9) and in 187 ET patients described by Bazzan et al. (10) . The natural history of thrombocythemia was featured by a high incidence of microcirculatory disturbances at platelet counts between 400 and 1,500 x 109/L in 36 patients with ET and 28 patients < 40 years of age with polycythemia described by Frezzato et al. (11) and in 22 ET/polycythemia patients described by Fr6hli et al. (12) . The increased platelet count in excess of 400 x 109/L is the main causative risk factor for microvascular circulation disturbances (4-9) and may lead to arterial thrombosis, including myocardial infarction and stroke in young, adult, and elderly ET patients if left untreated (7) (8) (9) (10) (11) (12) (13) . The arterial thrombotic manifestations in a large series of ET patients from retrospective clinical studies were described as microcirculatory disturbances in about 30%-40% and major arterial thrombosis (e.g., transient ischemic attacks, stroke, myocardial infarction, and peripheral arterial occlusions) in about 20%-25%. In contrast, the incidence of deep venous thrombosis was low (<5%) (8, 14, 15) .
Age >60 years was a risk factor of major vascular complications in two large studies of 100 and 148 ET patients, respectively (14, 15) . Increasing age has been recognized as a risk factor of arterial and venous thrombosis in the general population and in all types of thrombotic conditions such as the antiphospholipid syndrome and hereditary thrombophilia. The presence of one of the well-known risk factors for vascular disease, such as hypertension, hypercholesterolemia, diabetes, and smoking, usually does not contribute to an additional increased risk of microvascular and major vascular thrombotic complications in thrombocythemia indicating that the increased number of platelets in excess of 400 x 109/L is the causative factor for the arterial thrombotic thrombophilia in thrombocythemia vera (9, 14, 15) . Essential thrombocythemia patients with platelet counts >1,500 x 109/L are at high risk for spontaneous and major bleeding complications mainly due to the acquisition of a functional von Willebrand factor deficiency by proteolytic degradation of the high molecular weight von Willebrand factor multimers at increasing platelet counts (16) (17) (18) (19) (20) . Therefore, high-risk ET patients are defined by age >60 (to 65), a history of major thrombosis, spontaneous mucocutaneous bleeding manifestations and/or platelet counts in excess of 1,500 x 109/L. Consequently, low-risk ET patients are < 65 years, have no history or manifestations of major thrombosis or bleeding symptoms, and have platelet counts <1,500 x 109/L.
NATURAL HISTORY OF ET
Low-and high-risk ET patients usually show early stage myeloproliferative disease in bone marrow smears and biopsy material, and there is no progression of the myeloproliferative activity during long-term follow-up (21, 22) . The biology of the myeloproliferative disorder in ET patients is featured by a benign proliferation of mature large megakaryocytes in the bone marrow with no, or slightly increased, cellularity (21) (22) (23) (24) (25) (26) . In the bone marrow of ET patients, granulopoiesis and erythropoiesis are usually normal. There is no myelofibrosis in 99% of the cases at time of diagnosis of ET and few or no changes towards pleomorphy of the megakaryocytes or myelofibrosis can be found in long-term follow-up bone marrow biopsies from ET patients under no or minimal treatment (22, (24) (25) (26) . Essential thrombocythemia can be regarded as a benign myeloproliferative disorder with a normal life expectancy (9, 27) . Therefore, the only objective aim that can be achieved in treating symptomatic low-and high-risk ET patients is morbidity reduction of ET-related minor and major thrombotic complications and bleeding symptoms.
Aspirin is the criterion standard of antiplatelet therapy in ET for treatment and for the secondary prevention of microvascular disturbances, including erythromelalgia, digital ischemia, superficial thrombophlebitis, and the cerebral ischemic attacks of ET (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . In ET patients with painful erythromelalgic ischemic circulation disturbances, a large (500 mg/day) starting dose of aspirin immediately inhibits platelet cyclooxygenase activity completely relieving the erythromelalgic pain within a few hours followed by reversal of the inflammatory and ischemic circulation disturbances of the toes (2, 4) . With a low (50-100 mg/day) starting dose of aspirin for the treatment of microvascular circulation disturbances in ET, it takes a few days to 1 week for aspirin to accumulate gradually until complete inhibition of platelet cyclooxygenase is achieved to relieve the erythromelalgic circulation disturbances (2, 4) . The optimal effective dose of aspirin for the long-term prophylaxis of microvascular circulation disturbances in ET is unknown. An aspirin dose of 100 mg/day (or 80 mg/day) is generally recommended, but recent data indicate that daily doses of aspirin as low as 40-50 mg daily may be effective for the primary and secondary prevention of platelet-dependent vascular complications in ET patients (28) (29) (30) (31) (32) (33) (34) . The indication of aspirin is uncertain and should be used with caution in asymptomatic ET patients in whom the diagnosis of ET is made by routine blood investigation or by chance (13) . Therefore, the routine use of aspirin in asymptomatic ET patients is not advocated (13) . Clear indications of aspirin in ET patients are the presence and history of microvascular circulation disturbances including erythromelalgia, digital ischemia, cerebral ischemic attacks, visual disturbances, and superficial thrombophlebitis, which already may occur at a platelet count in >300, up to 1,000 x 109/L, or even up to 1,500 x 109/L (2-9,25,26). The relief of erythromelalgic ischemic circulation disturbances by low-dose aspirin in ET patients is associated with the correction of an increased platelet consumption and a significant rise of the platelet counts in the peripheral blood (30, 31) . The long-term use of low-dose aspirin for thrombosis prophylaxis in ET patients usually does not provoke bleeding at platelet counts between 400 and 1,000 x 109/L but may elicit bleeding at platelet counts > 1,000 x 10~/L (9). Despite the lack of evidence, clinicians tend to prescribe plateletlowering agents when the platelet counts exceed 1,000 x 109/L. Aspirin is relatively contraindicated in ET patients with previous bleeding episodes or with platelet counts >1,500 x 109/L.
CLEAR INDICATIONS OF PLATELET REDUCTIVE TREATMENT IN ET
Clear contraindications for the use of aspirin in ET patients that point to the need of platelet reductive therapy include: (a) a history or the presence of ETrelated bleeding episodes, (b) symptomatic ET patients with platelet counts >1,500 x 109/L, (c) bleeding while on aspirin for treatment and prevention of vascular complications, (d) side effects of aspirin, such as gastritis (8, 9, 13) . Clear indications for platelet-reductive treatment in high-risk ET patients are shown in Tablel. Reduction of platelet count to below 1,000 x 109/L is associated with relief and no recurrence of bleeding symptoms. The risk of vascular complications by reduction of the platelet count to <400 x 109/L is low (4) (5) (6) (7) (8) (9) 17) . There is good evidence that inadequate reduction of platelet count (>400 x 109/L) is associated with a continuous risk of vascular complications (4) (5) (6) (7) (8) (9) 29) . Effective prevention of vascular complications in ET at platelet counts >400 x 109/L of inadequately treated patients with plateletlowering agents is easily achieved with the addition of low-dose aspirin (50 mg/day) (9, (28) (29) (30) (31) (32) (33) (34) . High-risk ET patients over 60 to 65 years of age with the presence of a vascular risk factor and a history of major thrombosis do have a clear indication for low-dose aspirin, platelet reduction, plus adequate treatment of the underlying vascular disorder or risk factor. In a prospective clinical trial of 144 ET patients, Cortelazzo et al. (35) observed that 2 of 56 high-risk ET patients on hydroxyurea (HU) had major thrombotic events (one stroke, one myocardial infarction) and that 14 of 58 high-risk ET patients in the control group had minor microcirculatory disturbances in 12, major thrombosis in 1, and deep vein thrombosis in 1. In this study, 69% of the control group and 70% of the HU-treated ET patients received antiplatelet drugs, aspirin or ticlopidine. However, 10 of the 16 symptomatic patients in the HU arm (n = 2) and the control arm (n = 14) were not on aspirin treatment at time of the thrombotic event. The main conclusion from this study is that platelet reduction by HU as compared to no cytoreductive treatment in high-risk ET patients is effective in reducing the microcirculatory thrombotic circulation disturbances. The second conclusion is that high-risk ET patients have a high risk for recurrent microvascular circulation disturbances when not on low-dose aspirin. Therefore, it can be predicted that a direct comparison of HU versus low-dose aspirin in high-risk ET patients would be equally effective for the prevention of vascular complications. This issue can only be solved in a prospective clinical trial to address the question whether low-dose aspirin at platelet counts between 400 and 1,500 x 109/L versus correction of platelet counts by platelet-lowering drugs are equally effective to prevent minor and major thrombotic events in symptomatic ET patients with a history of transient ischemic attacks, minor stroke, or myocardial infarction in the absence of vascular disease or other risk factors (36) .
LEUKEMOGENICITY OF PLATELET REDUCTIVE AGENTS
Evidence is accumulating that HU is not a harmless drug (37) (38) (39) (40) (41) (42) . In a recent report, acute leukemia or myelodysplastic syndrome developed after a median followup of 8.2 years in 17 (4.5%) of 326 ET patients treated with HU in 251, pipobroman in 43, busulfan in 41, and 3zP in 40 patients (37) . In the randomized clinical trial of 114 ET patients of Cortelazzo et al. (35) , the investigators observed the occurrence of acute leukemia or myelodysplastic syndrome in 7% of 56 HU-treated and no acute leukemia or myelodysplastic syndrome in 58 untreated high-risk ET patients after a follow-up period of 6.1 years (41) . These data indicate that HU for the reduction of platelet counts to prevent of vascular complications in ET may be leukemogenic, an important consideration when deciding whether or not to commit symptomatic younger patients with ET to continuous long-term therapy with this drug (38) (39) (40) (41) . There is a pressing need for prospective controlled clinical trials to establish the clear indications, efficacy, and toxicity profiles of low-dose aspirin versus cytoreductive treatment in the different subsets of low-risk, high-risk, young, and elderly ET patients. Presently, it seems reasonable to treat young (<65 years) high-risk ET patients with a clear indication for long-term platelet reductive therapy, preferentially, with the nonleukemogenic agents interferon or anagrelide and not with HU (42) ( Table 1) .
